Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LOXO-338 · 1 trial · 7 indications
Measured by the number of patients with dose-limiting toxicities (DLTs)
Measured by the appropriate disease specified response criteria as appropriate to tumor type
Measured by the number of patients with dose-limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| LOXO-338 (Monotherapy) | EXPERIMENTAL | LOXO-338 administered orally. |
| LOXO-338 + Pirtobrutinib (Combination) | EXPERIMENTAL | LOXO-338 administered orally in combination with pirtobrutinib |
| Name | Type | Description |
|---|---|---|
| LOXO-338 | DRUG | Oral |
| Pirtobrutinib | DRUG | Oral |
Inclusion Criteria: * B-cell malignancy. * Patients must have received prior therapy. * Patients must have an objective indication for therapy. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. * Anticipated life expectancy of greater than or equal to (≥) 12 weeks. * Adequat...
LOXO-338 is an investigational small molecule being developed for the treatment of B-cell chronic lymphocytic leukemia and other advanced blood cancers, including B-cell marginal zone lymphoma, non-Hodgkin lymphoma, multiple myeloma, Waldenstrom macroglobulinemia, and mantle-cell lymphoma.
LOXO-338 is being developed by Eli Lilly and Company (NYSE: LLY). The drug is currently in Phase 1 clinical development for oncology indications.
LOXO-338 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study of the oral drug in patients with advanced blood cancers has been completed.
LOXO-338 has one completed Phase 1 clinical trial, NCT05024045, titled "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers." The trial enrolled 27 participants across the United States, France, Italy, and Poland.
No alternative names for LOXO-338 have been disclosed. The drug is identified by its investigational code name LOXO-338 and is being developed by Eli Lilly and Company.